Biotech Values

[TraderUsa]

OncoSec Medical (ONCS) Targets $47 Billion Cancer Market

NEW YORK, NY--(Marketwire - Mar 5, 2012) - Investment Opinion highlighting Dendreon Corp. (NASDAQ: DNDN), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), and OncoSec Medical, Inc. (OTCBB: ONCS). OncoSec Medical, a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic diseases, recently announced that the company has been highlighted in the March issue of Medical Device & Diagnostic Industry (MDDI) outlining development of its technology platform for treatment of rare and deadly skin cancers.

OncoSec uses electroporation which dramatically facilitates the ability of chemotherapy drugs to penetrate the cell, reducing the amount of drugs needed for treatment while increasing the effectiveness. At $47.7 billion, cancer is one of the largest and fastest growing markets in the medical industry and OncoSec is becoming a leading innovator in the fight against metastatic melanoma and Merkel cell carcinoma with the company's promising OMS ElectroOncology treatment platform.

Punit Dhillon, President and CEO of OncoSec, stated, "The treatment approach is potent. We can see a 4,000 to 10,000 fold increase in the movement of the agent into the cell." Substantially increasing the cellular uptake of chosen therapeutic agents can minimize the dose required to destroy cancer cells and spare healthy tissues. In addition, by enhancing the delivery mechanism of treatment, the side effects of non-targeted cancer-treatment protocols such as traditional chemotherapy can be drastically reduced.
Last week, Dendreon Corp. announced new executive appointments, Ariad Pharmaceuticals reported its 2011 financial results, and Onyx Pharmaceuticals completed the enrollment of phase 3 trials for the potential treatment of relapsed myeloma. The MDDI article highlights OncoSec as having the potential to push electroporation to the forefront of cancer treatment. The article also notes the company's upcoming milestones for 2012. Select the link to view the entire article on OncoSec Medical Incorporated:
http://www.mddionline.com/article/oncoSec-could-revolutionize-oncology-therapy

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Capital News Circuit twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Source: http://www.marketwire.com/press-release/oncosec-medical-oncs-targets-47-billion-cancer-market-1627661.htm